Q-omics provides the consensus-scored MAP1LC3P profile across patient tissues and cancer cell-line models. MAP1LC3P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAP1LC3P is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MAP1LC3P RNA expression shows 6,636 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, COAD, and ESCA as cancer lineages where MAP1LC3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1LC3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1LC3P survival associations across molecular data types. MAP1LC3P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1LC3P RNA expression–survival associations across cancer types. High MAP1LC3P expression shows unfavorable associations in ACC, KIRC, SKCM, ESCA, GBM and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAP1LC3P RNA expression.
This table summarizes MAP1LC3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MAP1LC3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1LC3P shows lower tumor expression in COAD and LUSC and higher tumor expression in KICH, STAD and KIRC. The COAD box plot shows higher MAP1LC3P RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p = .002).
This table shows molecular features associated with MAP1LC3P in patient tissues and cancer cell lines. In patient samples, MAP1LC3P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
